Vident Advisory’s Core Laboratories CLB Stock Holding History

Vident Advisory’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$117K	Hold	10,019	–	–	﹤0.01%	1877
2026 Q1	$168K	Buy	+10,019	New	+$179K	﹤0.01%	1745

Other funds holding CLB

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vident Advisory's CLB Position: Q2 2026 in Review

Vident Advisory held its Core Laboratories (CLB) position steady in Q2 2026 at 10,019 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #1877.

Vident Advisory first reported a position in CLB in Q1 2026 and has held it in 2 quarters since. The position peaked at $168K in Q1 2026. 186 funds tracked by Wall St. Rank hold CLB as of Q2 2026.

Vident Advisory held 10,019 shares of Core Laboratories worth $117K as of Q2 2026.
Vident Advisory left its Core Laboratories share count unchanged in Q2 2026.
Core Laboratories made up ﹤0.01% of Vident Advisory's portfolio in Q2 2026, its #1877 holding.
Vident Advisory first reported a position in Core Laboratories in Q1 2026 and has held it in 2 quarters since.
Vident Advisory's Core Laboratories position peaked at $168K in Q1 2026.
186 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.